Arteriosclerosis coronary artery – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Arteriosclerosis coronary artery – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of SP16 to Prevent Acute Kidney Injury in Patients with Chronic Kidney Disease Undergoing Heart Surgery with Heart-Lung Machine https://clinicaltrials.eu/trial/study-of-sp16-to-prevent-acute-kidney-injury-in-patients-with-chronic-kidney-disease-undergoing-heart-surgery-with-heart-lung-machine/ Wed, 29 Apr 2026 15:08:15 +0000 https://clinicaltrials.eu/trial/study-of-sp16-to-prevent-acute-kidney-injury-in-patients-with-chronic-kidney-disease-undergoing-heart-surgery-with-heart-lung-machine/ This clinical trial is studying people who have Chronic Kidney Disease along with heart valve problems or other Cardiovascular Disease who need planned heart surgery. The study will test a treatment called SP16, which is an anti-inflammatory medication given as an injection under the skin. Some participants will receive SP16 while others will receive placebo. The purpose of the study is to evaluate the safety of SP16 and to see if it can prevent a serious complication called Acute Kidney Injury that can occur after heart surgery in people with existing kidney disease. During the surgery, a heart-lung-machine, also called cardiopulmonary bypass, will be used to temporarily take over the work of the heart and lungs.

The study will involve people with chronic kidney disease who are scheduled for heart surgery such as coronary artery bypass grafting (a procedure to improve blood flow to the heart), aortic valve surgery (repair or replacement of the valve between the heart and the main artery), mitral valve surgery (repair or replacement of the valve between the upper and lower chambers on the left side of the heart), or a combination of these procedures. Participants will receive the study medication or placebo before their surgery. After the surgery, they will be carefully monitored in the hospital to check their kidney function by measuring substances in their blood and urine. The medical team will watch for any side effects or complications, particularly during the first 72 hours after surgery.

The observation period will continue for about 90 days after the surgery. During this time, participants will have follow-up visits where doctors will check their kidney function, heart function using ultrasound imaging of the heart called echocardiography, and measure specific markers in the blood such as NT-proBNP, which indicates how well the heart is working. The study will track whether participants develop kidney injury after surgery, how severe it becomes, how long it takes for kidney function to return to normal, and whether any participants need dialysis, which is a treatment that filters the blood when the kidneys cannot do so properly. The medical team will also monitor oxygen levels in the blood and record any adverse events or serious health problems that occur throughout the study period.

]]> Study of Rosuvastatin Effects on Coronary Artery Plaque Volume in Patients with Stable Chest Pain Using CT Imaging https://clinicaltrials.eu/trial/study-of-rosuvastatin-effects-on-coronary-artery-plaque-changes-using-ct-scan-imaging-in-patients-with-stable-chest-pain/ Wed, 29 Apr 2026 15:06:21 +0000 https://clinicaltrials.eu/trial/study-of-rosuvastatin-effects-on-coronary-artery-plaque-changes-using-ct-scan-imaging-in-patients-with-stable-chest-pain/ This study focuses on patients with Coronary Artery Disease who experience stable chest pain. The research examines how statin therapy affects the characteristics of coronary artery plaques, which are deposits that can build up in blood vessels of the heart. The study uses Coronary Computed Tomography Angiography, a specialized imaging technique that creates detailed pictures of heart blood vessels.

The treatment involves comparing two medications: Xeter (which contains rosuvastatin, a type of statin medication that helps lower cholesterol) and placebo. The study aims to measure changes in the volume and composition of plaques in heart arteries after three months of treatment.

During the study, participants will undergo heart imaging at the beginning of the study and after three months of taking either Xeter or placebo. The medication is taken as a film-coated tablet by mouth. The maximum daily dose of Xeter is 40 milligrams, and treatment continues for up to 12 months. The study will track various aspects of heart health and monitor how the plaques in the arteries may change over time.

]]> Study on the Effects of Semaglutide, Dapagliflozin, and Metformin in Patients with Coronary Artery Disease and Prediabetes https://clinicaltrials.eu/trial/study-on-the-effects-of-semaglutide-dapagliflozin-and-metformin-in-patients-with-coronary-artery-disease-and-prediabetes/ Wed, 29 Apr 2026 14:47:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-semaglutide-dapagliflozin-and-metformin-in-patients-with-coronary-artery-disease-and-prediabetes/ This clinical trial is focused on studying the effects of certain medications on patients with coronary artery disease and prediabetes. Coronary artery disease is a condition where the blood vessels supplying the heart become narrowed or blocked, while prediabetes is a state where blood sugar levels are higher than normal but not yet high enough to be classified as diabetes. The study will involve the use of medications such as semaglutide (known by the brand name Rybelsus), dapagliflozin (known by the brand name Forxiga), and metformin (known by the brand name Formetic). These medications are taken orally in tablet form.

The purpose of the study is to compare the effectiveness of these medications in slowing down or reversing the buildup of plaque in the arteries of the heart, which is a key factor in coronary artery disease. The study will last for 24 months, during which participants will receive one of the medications along with advice on diet and lifestyle changes. The progress of the disease will be monitored using a special type of X-ray called computed tomography (CT), which provides detailed images of the heart and its blood vessels.

Participants will be randomly assigned to receive either semaglutide, dapagliflozin, metformin, or a placebo. The study aims to observe how these treatments affect the progression of coronary artery disease and other health factors such as weight, blood pressure, and cholesterol levels. The results will help determine which medication is most effective in managing coronary artery disease in patients with prediabetes.

]]>